Radiopharmaceuticals (PDF)

Dr. Ferdinando Calabria graduated with a degree in Medicine in 2005 and specialized in Nuclear Medicine in 2009 at the University of Rome "Tor Vergata." As a resident in Nuclear Medicine, he began studying the molecular pathways of new PET radiopharmaceuticals. His specific scientific interest was in deepening our knowledge of the physio-pathological features of PET radiopharmaceuticals bio-distribution in order to verify further diagnostic applications. Another topic during this period was the evaluation of the potential added value of rising hybrid imaging with SPECT/CT and PET/CT scanners. Since 2010 he has led the Department of Nuclear Medicine at Neuromed Research Institute, where he has focused on prostate cancer imaging with 18F-choline PET/CT and brain tumor imaging with 18F-DOPA PET/CT. In 2015 his scientific interest shifted to the imaging of the brain, working on a hybrid PET/MRI 3T scanner installed at the Italian National Research Council. Here, he started developing an interest in applying 18F-FDG PET/MRI for patients with neurodegenerative diseases and 18F-FET for neuro-oncology, using a multidisciplinary network approach. He is currently exploring the role of advanced hybrid imaging with SPECT/CT and PET/CT in oncological patients, at the national public Hospital "Mariano Santo" in southern Italy. The author of over 40 scientific papers listed in PubMed, he has also served as a reviewer for the major specialized scientific journals of nuclear medicine.

Prof. Orazio Schillaci graduated with a degree in Medicine in 1990 and specialized in Nuclear Medicine in 19942 at the University of Rome "La Sapienza." He began his scientific work at the University of L'Aquila: during this important period, Schillaci started exploring molecular imaging, with an emphasis on SPECT for neuroendocrine tumors. After a research stay in California, USA, he became a Professor of Nuclear Medicine at the University of Rome "Tor Vergata" in 2001. Since 2008 he has led